The company’s revenue from operations increased 43% year-on-year to ₹167 crore, compared with ₹116.8 crore in the year-ago period, driven by strong topline growth during the quarter.
Operating performance also improved significantly. EBITDA surged 86.6% year-on-year to ₹32.1 crore from ₹17.2 crore in the corresponding quarter last year. The EBITDA margin expanded to 19.2% from 14.7% a year earlier, reflecting improved operating profitability.
The company announced its financial results after its Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 at its meeting held on 17 July.
Alongside the quarterly results, the board approved the reappointment of Managing Director Chintan Nitinkumar Shah and Whole-time Directors Ajaykumar Mansukhlal Patel and Shekhar Rasiklal Somani for a further term of three years, subject to shareholders’ approval at the forthcoming annual general meeting.
The board also approved a proposed capacity expansion at the company’s new greenfield manufacturing unit at Dahej-III in Gujarat. The expansion involves the installation of an aggregate reactor capacity of 344 kilolitres with an estimated investment of around ₹200 crore, to be financed through a combination of internal accruals and debt.
Shares of Tatva Chintan Pharma Chem closed 0.83% higher at ₹1,430 on the NSE on Friday.
